TipRanks
Advertisement
Advertisement
Mediar Therapeutics CMO to Discuss IPF Trial Design at Industry Summit
PremiumPrivate CompaniesMediar Therapeutics CMO to Discuss IPF Trial Design at Industry Summit
12d ago
Mediar Therapeutics Highlights Focus on Idiopathic Pulmonary Fibrosis
Premium
Private Companies
Mediar Therapeutics Highlights Focus on Idiopathic Pulmonary Fibrosis
21d ago
Mediar Therapeutics Highlights Phase 2 Fibrosis Program in Pulmonary Fibrosis Awareness Month
Premium
Private Companies
Mediar Therapeutics Highlights Phase 2 Fibrosis Program in Pulmonary Fibrosis Awareness Month
1M ago
Mediar Therapeutics Collaboration Highlights Antifibrotic Pipeline Focus
PremiumPrivate CompaniesMediar Therapeutics Collaboration Highlights Antifibrotic Pipeline Focus
2M ago
Mediar Therapeutics Enters R&D Collaboration On Fibro-Inflammatory Antibody Therapies
Premium
Private Companies
Mediar Therapeutics Enters R&D Collaboration On Fibro-Inflammatory Antibody Therapies
2M ago
Mediar Therapeutics Strikes Option-Backed Fibrosis Alliance With Ono, Advances Antibody Pipeline
Premium
Private Companies
Mediar Therapeutics Strikes Option-Backed Fibrosis Alliance With Ono, Advances Antibody Pipeline
2M ago
Community Engagement Underscores Mediar Therapeutics’ Focus on Kidney Disease
PremiumPrivate CompaniesCommunity Engagement Underscores Mediar Therapeutics’ Focus on Kidney Disease
3M ago
Mediar Therapeutics Strengthens Scientific Leadership Through Internal Promotions
Premium
Private Companies
Mediar Therapeutics Strengthens Scientific Leadership Through Internal Promotions
3M ago
Mediar Therapeutics Advances Kidney Fibrosis Portfolio With First-in-Human MTX-439 Trial
Premium
Private Companies
Mediar Therapeutics Advances Kidney Fibrosis Portfolio With First-in-Human MTX-439 Trial
4M ago

Trending

Name
Price
Price Change
S&P 500
―
Dow Jones
―
Nasdaq 100
―